Brian Daniel Webster Sells 15,000 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $22.80, for a total value of $342,000.00. Following the sale, the insider directly owned 394,786 shares of the company’s stock, valued at approximately $9,001,120.80. This represents a 3.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Brian Daniel Webster also recently made the following trade(s):

• On Monday, December 29th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $26.59, for a total value of $398,850.00.

Kestra Medical Technologies Trading Up 2.6%

NASDAQ:KMTS opened at $23.60 on Thursday. Kestra Medical Technologies, Ltd. has a 12-month low of $13.25 and a 12-month high of $30.00. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.26. The stock’s 50 day simple moving average is $25.48 and its 200-day simple moving average is $22.23. The firm has a market cap of $1.38 billion and a P/E ratio of -7.44.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Stifel Nicolaus set a $30.00 target price on shares of Kestra Medical Technologies in a research note on Friday, December 12th. BTIG Research began coverage on shares of Kestra Medical Technologies in a research report on Tuesday, November 18th. They issued a “buy” rating and a $32.00 price objective for the company. Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Sunday, September 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Wednesday, December 24th. Finally, The Goldman Sachs Group set a $24.00 price target on Kestra Medical Technologies in a research note on Friday, January 16th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $29.00.

Institutional Trading of Kestra Medical Technologies

Several large investors have recently bought and sold shares of KMTS. Eventide Asset Management LLC increased its position in shares of Kestra Medical Technologies by 285.7% in the second quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company’s stock valued at $17,584,000 after buying an additional 785,557 shares in the last quarter. Millennium Management LLC acquired a new stake in Kestra Medical Technologies in the 1st quarter valued at about $11,036,000. Geode Capital Management LLC increased its holdings in Kestra Medical Technologies by 718.5% during the 2nd quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock valued at $5,395,000 after acquiring an additional 285,579 shares in the last quarter. Alliancebernstein L.P. raised its position in Kestra Medical Technologies by 13.7% during the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock worth $35,449,000 after acquiring an additional 179,885 shares during the last quarter. Finally, UBS Group AG lifted its holdings in shares of Kestra Medical Technologies by 173.7% in the third quarter. UBS Group AG now owns 200,150 shares of the company’s stock valued at $4,756,000 after purchasing an additional 127,026 shares in the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.